1 Min Read
May 21 (Reuters) - Genomic Health Inc:
* NEW DATA REINFORCE POSITIVE IMPACT OF THE ONCOTYPE DX® GENOMIC PROSTATE SCORE™ TEST IN GUIDING TREATMENT DECISIONS Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.